Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have locally advanced/borderline resectable hepatocellular carcinoma.~2. Must have measurable disease.~3. Age ≥18 years.~4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~5. Patients must have adequate organ and marrow function defined by study-specified laboratory tests.~6. Patients must have adequate liver remnant and function.~7. Antiviral therapy per local standard of care for hepatitis B.~8. Woman of child bearing potential must have a negative pregnancy test.~9. Must use acceptable form of birth control while on study.~10. Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~1. Fibrolamellar carcinoma or mixed HCC.~2. Chemotherapy, radiotherapy, investigational therapy, or surgery less than 6 months prior to trial registration.~3. Concomitant Anticoagulation therapy.~4. Any GI or pulmonary risks of bleeding.~5. History of HIV Infection.~6. Active co-infection with hepatitis B and hepatitis C.~7. Active co-infection with hepatitis B and hepatitis D.~8. Has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy.~9. History of any autoimmune disease requiring systemic treatment within the past 2 years. Any patient bearing an allograft is not eligible.~10. Any additional malignancies with treatment or life-limiting cancers. Superficial bladder cancer, non-melanoma skin cancers, or low grade prostate cancer not requiring therapy would not exclude participation in this trial.~11. Uncontrolled intercurrent illness.~12. Corrected QT interval calculated by the Fridericia formula.~13. Uncontrolled high blood pressure.~14. Are pregnant or breastfeeding.~15. Any gastrointestinal (GI) disorders.~16. Any certain study-specified heart conditions 6 months prior to enrollment.~17. Major surgery within 2 months before enrollment.~18. Have any evidence of moderate or severe ascites.~19. Any untreated or incompletely treated varices with bleeding or high-risk bleeding.~20. Inability to swallow intact tablets.~21. Known or suspected hypersensitivity to study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).